UPDATE: Capricor Therapeutics (CAPR) — The August 22 Binary Just Got Cancelled

The 10-Q discloses that FDA has agreed to review a BLA amendment with 24-month HOPE-3 extension data supporting a “refined indication,” with the PDUFA date extended accordingly. CAPR +58% to $6.65.